Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali McBride

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
Pharmacotherapy|October 30, 2013
Author's reply: To PMID 23456733Ali McBride
Journal of Hematology & Oncology|December 15, 2012
Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignanciesAli McBride, Peter Westervelt
Journal of the Advanced Practitioner in Oncology|November 21, 2017
Outpatient Management of the Hematopoietic Stem Cell Transplant PatientSandra Kurtin, Ali McBride
Journal of the Advanced Practitioner in Oncology|August 7, 2018
Risk Assessment and Risk-Adapted Treatment Selection: A Case-Based Approach for Chronic Lymphocytic LeukemiaSandra Kurtin, Ali McBride
Critical Reviews in Oncology/Hematology|June 19, 2016
Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilarAmit B Agarwal, Ali McBride
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 5, 2012
Drug shortages in oncologyAli McBride, Philip E Johnson
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|April 21, 2012
Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancerAli McBride, Sara K Butler
Expert Review of Anticancer Therapy|March 13, 2013
Proteasome inhibitors in the treatment of multiple myelomaAli McBride, Patricia Y Ryan
Oncology (Williston Park, N.Y.)|October 19, 2013
Oral oncolytics: part 1--financial, adherence, and management challengesRobert Mancini, Ali McBride, Mary Kruczynski
Leukemia Research|May 6, 2021
Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphomaAli McBride, Karen MacDonald, Ivo Abraham
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
Pharmacotherapy|October 30, 2013
Author's reply: To PMID 23456733Ali McBride
Journal of Hematology & Oncology|December 15, 2012
Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignanciesAli McBride, Peter Westervelt
Journal of the Advanced Practitioner in Oncology|November 21, 2017
Outpatient Management of the Hematopoietic Stem Cell Transplant PatientSandra Kurtin, Ali McBride
Journal of the Advanced Practitioner in Oncology|August 7, 2018
Risk Assessment and Risk-Adapted Treatment Selection: A Case-Based Approach for Chronic Lymphocytic LeukemiaSandra Kurtin, Ali McBride
Critical Reviews in Oncology/Hematology|June 19, 2016
Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilarAmit B Agarwal, Ali McBride
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 5, 2012
Drug shortages in oncologyAli McBride, Philip E Johnson
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|April 21, 2012
Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancerAli McBride, Sara K Butler
Expert Review of Anticancer Therapy|March 13, 2013
Proteasome inhibitors in the treatment of multiple myelomaAli McBride, Patricia Y Ryan
Oncology (Williston Park, N.Y.)|October 19, 2013
Oral oncolytics: part 1--financial, adherence, and management challengesRobert Mancini, Ali McBride, Mary Kruczynski
Leukemia Research|May 6, 2021
Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphomaAli McBride, Karen MacDonald, Ivo Abraham
Pageof 15